The tissue‐specific metabolic effects of the PPARα agonist ciprofibrate in insulin‐resistant male individuals: a double‐blind, randomized, placebo‐controlled crossover study
Authors' conclusion
Ciprofibrate treatment increased hepatic lipid accumulation and lowered MRgluc, without affecting whole-body insulin sensitivity. Furthermore, parameters of cardiac function or cardiac energy status were not altered upon ciprofibrate treatment.
Study context
- Population
- Insulin-resistant male volunteerscrossover
- Participants
- 10 volunteers
- Comparison
- Ciprofibrate 100 mg/d vs placebo for 5 weeks
- Primary endpoint
- Insulin-stimulated MRgluc measured by dynamic 18 F-FDG-PET
- Follow-up
- 5 weeks
Methodological detailsdouble-blind, placebo-controlled, crossover
- Double-blind
- Placebo-controlled
- Crossover
Primary result
As reported in the abstract
Insulin-stimulated MRgluc
- Ciprofibrate decreased insulin-stimulated hepatic metabolic rate of glucose (MRgluc)
- Myocardial net MRgluc tended to decrease after ciprofibrate
Further findings
Whole-body insulin sensitivity, energy metabolism and body composition
- Unchanged after ciprofibrate
Hepatic lipid content
- Increased with ciprofibrate
Cardiac function and cardiac energy status
- No effect of ciprofibrate
PPAR-related gene expression in muscle
- No changes found
Original publication
The tissue‐specific metabolic effects of the PPARα agonist ciprofibrate in insulin‐resistant male individuals: a double‐blind, randomized, placebo‐controlled crossover study. Obesity (Silver Spring). Published 5 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →